Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4625 |
Optical Activity | ( - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCc1cc(c([C@]2([H])C=C(C)CC[C@@]2([H])C(=C)C)c(c1)O)O
InChI
InChIKey=QHMBSVQNZZTUGM-ZWKOTPCHSA-N
InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18+/m0/s1
Molecular Formula | C21H30O2 |
Molecular Weight | 314.4625 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24854329 | https://www.gwpharm.com/products-pipeline
Cannabidiol is the major nonpsychoactive ingredient in cannabis. Cannabidiol demonstrates a range of effects that may be therapeutically useful, including anti-seizure, antioxidant, neuroprotective, anti-inflammatory, analgesic, anti-tumor, anti-psychotic, and anti-anxiety properties. Exact mechanism of action of cannabidiol is not known, but may include effects on the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 glycine receptors. GW Pharmaceuticals successfully developed the world’s first prescription medicine derived from the cannabis plant, Sativex® (buccal spray containing delta-9-tetrahydrocannabinol and cannabidiol) now approved in over 29 countries outside of the United States for the treatment of spasticity due to Multiple Sclerosis. GW Pharmaceuticals is developing Epidiolex® (a liquid formulation of pure plant-derived cannabidiol) for certain rare and severe early-onset, drug-resistant epilepsy syndromes.
Originator
Sources: Adams R, Hunt M, Clark JH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. J Am Chem Soc. 1940;62:196-200. | Mechoulam R, Shvo Y. Hashish. 1. Structure of Cannabidiol. Tetrahedron. 1963;19(12):2073-8
Curator's Comment:: Although cannabidiol was isolated from marijuana extract in 1940 by Adams et al., for almost 25 years no further work has been reported, except for a few early works about its isolation. Only in 1963 its exact chemical structure was elucidated by Mechoulam and Shvo. https://www.ncbi.nlm.nih.gov/pubmed/18833429
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16258853 |
|||
Target ID: CHEMBL4794 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11606325 |
3.2 µM [EC50] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27754480 |
11.0 nM [Ki] | ||
Target ID: CHEMBL1075322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17876302 |
445.0 nM [IC50] | ||
Target ID: CHEMBL1075092 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22585736 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | SATIVEX Approved UseSativex is used in multiple sclerosis (MS) to improve symptoms related to muscle stiffness. This is also called “spasticity”. Spasticity means there is an increase in ‘muscle tone’ which makes the muscles feel more stiff or rigid. This means it is more difficult than normal to move the muscle. Sativex is used when other medicines have not helped your muscle stiffness. |
|||
Primary | SATIVEX Approved UseSATIVEX® buccal spray is indicated as adjunctive analgesic treatment in adult patients with advanced cancer who experience moderate to severe pain during the highest tolerated dose of strong opioid therapy for persistent background pain. |
|||
Primary | EPIDIOLEX Approved UseUnknown |
|||
Primary | EPIDIOLEX Approved UseUnknown |
|||
Primary | EPIDIOLEX Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
330.3 ng/mL |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
541.2 ng/mL |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
292.4 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
327 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
782 ng/mL |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1588 ng/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1745 ng × h/mL |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3236 ng × h/mL |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1618 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2198 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3900 ng × h/mL |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
8670 ng × h/mL |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
56.41 h |
750 mg 2 times / day multiple, oral dose: 750 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
60.54 h |
1500 mg 2 times / day multiple, oral dose: 1500 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14.43 h |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
15.42 h |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6% |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6% |
6000 mg single, oral dose: 6000 mg route of administration: Oral experiment type: SINGLE co-administered: |
CANNABIDIOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Disc. AE: Transaminases increased... Other AEs: Transaminases increased, Decreased appetite... AEs leading to discontinuation/dose reduction: Transaminases increased (1.3%) Other AEs:Transaminases increased (8%) Sources: Decreased appetite (16%) Diarrhea (9%) Weight decreased (3%) Abdominal discomfort (3%) Somnolence (23%) Sedation (3%) Lethargy (4%) Fatigue (11%) Malaise (11%) Asthenia (11%) Irritability (9%) Agitation (9%) Insomnia (11%) Sleep disorder (11%) Poor quality sleep (11%) Aggression (3%) Anger (3%) Drooling (1%) Salivary hypersecretion (1%) Gait disturbance (3%) Infection viral (7%) Pneumonia (8%) Fungal infection (1%) Infection NOS (25%) Rash (7%) Hypoxia (3%) Respiratory failure (3%) |
20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Disc. AE: Transaminases increased... Other AEs: Transaminases increased, Decreased appetite... AEs leading to discontinuation/dose reduction: Transaminases increased (5.9%) Other AEs:Transaminases increased (16%) Sources: Decreased appetite (22%) Diarrhea (20%) Weight decreased (5%) Abdominal discomfort (3%) Somnolence (25%) Sedation (6%) Lethargy (8%) Fatigue (12%) Malaise (12%) Asthenia (12%) Irritability (5%) Agitation (5%) Aggression (5%) Anger (5%) Drooling (4%) Salivary hypersecretion (4%) Gait disturbance (2%) Infection viral (11%) Pneumonia (5%) Fungal infection (3%) Infection NOS (21%) Rash (13%) Hypoxia (3%) Gastroenteritis (4%) Insomnia (5%) Sleep disorder (5%) Poor quality sleep (5%) Respiratory failure (3%) |
50 mg/kg/day 1 times / day multiple, oral Dose: 50 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 50 mg/kg/day, 1 times / day Sources: |
healthy, adult n = 5 Health Status: healthy Age Group: adult Population Size: 5 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Drooling | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Fungal infection | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Salivary hypersecretion | 1% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Transaminases increased | 1.3% Disc. AE |
10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Asthenia | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Fatigue | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Insomnia | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Malaise | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Poor quality sleep | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Sleep disorder | 11% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Decreased appetite | 16% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Somnolence | 23% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection NOS | 25% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Abdominal discomfort | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Aggression | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Anger | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Gait disturbance | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Hypoxia | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Respiratory failure | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Sedation | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Weight decreased | 3% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Lethargy | 4% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection viral | 7% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Rash | 7% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Pneumonia | 8% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Transaminases increased | 8% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Agitation | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Diarrhea | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Irritability | 9% | 10 mg/kg/day 1 times / day multiple, oral Recommended Dose: 10 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 10 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 75 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 75 Sources: |
Infection viral | 11% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Asthenia | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Fatigue | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Malaise | 12% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Rash | 13% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Transaminases increased | 16% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Gait disturbance | 2% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Diarrhea | 20% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Infection NOS | 21% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Decreased appetite | 22% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Somnolence | 25% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Abdominal discomfort | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Fungal infection | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Hypoxia | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Respiratory failure | 3% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Drooling | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Gastroenteritis | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Salivary hypersecretion | 4% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Aggression | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Agitation | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Anger | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Insomnia | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Irritability | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Pneumonia | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Poor quality sleep | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Sleep disorder | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Weight decreased | 5% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Transaminases increased | 5.9% Disc. AE |
20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Sedation | 6% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Lethargy | 8% | 20 mg/kg/day 1 times / day multiple, oral Recommended Dose: 20 mg/kg/day, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg/day, 1 times / day Sources: |
unhealthy, 14 years (range: 2 - 48 years) n = 238 Health Status: unhealthy Condition: seizures associated with Lennox-Gastaut syndrome or Dravet syndrome Age Group: 14 years (range: 2 - 48 years) Sex: M+F Population Size: 238 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210365Orig1s000PharmR.pdf#page=20 Page: 20.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Hair analysis for delta(9)-THC, delta(9)-THC-COOH, CBN and CBD, by GC/MS-EI. Comparison with GC/MS-NCI for delta(9)-THC-COOH. | 2002 Aug 14 |
|
Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. | 2002 Dec 16 |
|
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects. | 2002 Dec 31 |
|
(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. | 2002 Dec 5 |
|
Cannabidiol: an overview of some pharmacological aspects. | 2002 Nov |
|
Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. | 2002 Nov 15 |
|
Fully automated determination of cannabinoids in hair samples using headspace solid-phase microextraction and gas chromatography-mass spectrometry. | 2002 Nov-Dec |
|
Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. | 2003 |
|
Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. | 2003 Apr |
|
Automated headspace solid-phase dynamic extraction for the determination of cannabinoids in hair samples. | 2003 Apr 23 |
|
Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. | 2003 Apr-Jun |
|
The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. | 2003 Aug |
|
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. | 2003 Aug 8 |
|
Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects? | 2003 Dec |
|
Cannabidiol-transdermal delivery and anti-inflammatory effect in a murine model. | 2003 Dec 12 |
|
A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. | 2003 Feb |
|
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | 2003 Feb 15 |
|
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. | 2003 Feb 25 |
|
The inheritance of chemical phenotype in Cannabis sativa L. | 2003 Jan |
|
[Weather-induced changes in cannabinoid content of hair]. | 2003 Jan-Feb |
|
Post-ischemic treatment with cannabidiol prevents electroencephalographic flattening, hyperlocomotion and neuronal injury in gerbils. | 2003 Jul 31 |
|
Gateways to clinical trials. | 2003 Jun |
|
Simultaneous detection of some drugs of abuse in saliva samples by SPME technique. | 2003 Jun 24 |
|
Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. | 2003 Nov |
|
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current. | 2003 Nov 14 |
|
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. | 2003 Nov 8 |
|
Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use? | 2003 Nov 8 |
|
Gamma-irradiation enhances apoptosis induced by cannabidiol, a non-psychotropic cannabinoid, in cultured HL-60 myeloblastic leukemia cells. | 2003 Oct |
|
Neuroscience. Stout guards of the central nervous system. | 2003 Oct 3 |
|
Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. | 2003 Sep |
|
(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. | 2004 Dec 15 |
|
Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. | 2004 Feb |
|
Effects of cannabidiol (CBD) on regional cerebral blood flow. | 2004 Feb |
|
Determination of cannabinoids in hemp food products by use of headspace solid-phase microextraction and gas chromatography-mass spectrometry. | 2004 Jan |
|
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). | 2004 Jan |
|
Medicinal cannabis extracts for the treatment of multiple sclerosis. | 2004 Jul |
|
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. | 2004 Jul 15 |
|
Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. | 2004 Jun |
|
Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. | 2004 Jun 18 |
|
Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. | 2004 Mar |
|
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. | 2004 Mar |
|
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. | 2004 May |
|
Cannabidiol lacks the vanilloid VR1-mediated vasorespiratory effects of capsaicin and anandamide in anaesthetised rats. | 2004 May 3 |
|
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. | 2004 Sep |
|
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. | 2005 Aug |
|
Effect of cannabis use in human brain activity. | 2005 Mar |
|
Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. | 2005 Mar 21 |
|
Cannabidiol prevents cerebral infarction via a serotonergic 5-hydroxytryptamine1A receptor-dependent mechanism. | 2005 May |
|
Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. | 2005 Sep |
|
Effects of RM-beta-CD on sublingual bioavailability of Delta9-tetrahydrocannabinol in rabbits. | 2005 Sep |
Patents
Sample Use Guides
SATIVEX® is provided as a buccal spray in a 5.5 ml vial, with each 100 microlitre spray providing 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). In patients with multiple sclerosis, the median daily dosage of SATIVEX® in the extension phase of the 4-week clinical trial was 5 sprays per day. The majority of patients required 12 sprays or less; dosage should be adjusted as needed and tolerated. There is limited experience with doses higher than 12 sprays per day. Some patients may require and may tolerate a higher number of sprays. In patients with pain in cancer, the median daily dosage of SATIVEX® was 8 actuations (sprays).
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27932991
in vitro pre-treatment of Human Gingival Mesenchymal Stem Cells with 5 uM Cannabidiol (CBD) can influence their expression profile
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:23:38 UTC 2021
by
admin
on
Fri Jun 25 21:23:38 UTC 2021
|
Record UNII |
19GBJ60SN5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/17/1959
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
471815
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
NCI_THESAURUS |
C274
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
444814
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
409313
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
609617
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
DSLD |
3397 (Number of products:162)
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
617417
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
521416
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
WHO-ATC |
N03AX24
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
452614
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
620417
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
696519
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
734820
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
806620
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
545316
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
482315
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
656618
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
736020
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
538916
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
WHO-ATC |
N02BG10
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
486115
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
610117
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
488315
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
510716
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
628818
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
549616
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
498215
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
668918
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
734620
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
438214
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
439414
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
421213
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
FDA ORPHAN DRUG |
450814
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
||
|
NCI_THESAURUS |
C105578
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2045371
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
CHEMBL190461
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
1089149
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | USP-RS | ||
|
Cannabidiol
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
SUB26600
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
C118452
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
CANNABIDIOL
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
10423
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
DB09061
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
1089161
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | USP-RS | ||
|
5288
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
19GBJ60SN5
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
13956-29-1
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
644019
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
D002185
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | |||
|
M3020
Created by
admin on Fri Jun 25 21:23:38 UTC 2021 , Edited by admin on Fri Jun 25 21:23:38 UTC 2021
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->INVERSE AGONIST | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Cannabidiol Class | Anxiolytic Antipsychotic | Analgesic | Anti-inflammatory | Antioxydant | Antispasmodic
|
||
|
TARGET -> INHIBITOR | |||
|
TARGET -> ACTIVATOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET->INVERSE AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE ACTIVE -> PARENT |
The major circulating metabolites include 7-hydroxy-cannabidiol (7-OH-CBD), which was approximately 38% of the parent based on AUC of cannabidiol.
MAJOR
|
||
|
METABOLITE -> PARENT |
MINOR
|
||
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
TWICE-DAILY DOSING FOR 7 DAYS |
|
||